COROT C ET AL: "Structure-activity relationship of macrocyclic and linear gadolinium chelates: Investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme", JOURNAL OF MAGNETIC RESONANCE IMAGING 199805 US, vol. 8, no. 3, May 1998 (1998-05), pages 695-702, XP008097347, ISSN: 1053-1807 (B1)

ANONYME: "NEPHROGENIC SYSTEMIC FIBROSIS: AN UNCOMMON AND DEBILITATING DISEASE POSSIBLY ASSOCIATED WITH GADOLINIUM CHELATES", GUERBET INFORMATION FOR HEALTHCARE PROFESSIONALS AND INVESTORS , 21 December 2007 (2007-12-21), pages 1-7, XP002499276, Villepinte, France Retrieved from the Internet: URL:http://www.guerbet.com/fileadmin/user_ upload/news/Updated_information_about_NSF_ 21_dec_2007.pdf [retrieved on 2008-10-13] (B1)

KIMURA J ET AL: "Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents", RADIATION MEDICINE - MEDICAL IMAGING AND RADIATION ONCOLOGY 200508 JP, vol. 23, no. 5, August 2005 (2005-08), pages 322-326, XP002499275, ISSN: 0288-2043 (B1)

US-A- 4 647 447 (B1)

US-A- 5 876 695 (B1)

US-A1- 2004 170 566 (B1)

WO-A-2007/121453 (B1)

WO-A-89/00052 (B1)

ZHU X ET AL: "Formation kinetics and stability studies on the lanthanide complexes of 1,4,7, 10-tetra-azacyclododecane-N,N',N'',N'''-te traacetic acid by capillary electrophoresis", ELECTROPHORESIS 2002 DE, vol. 23, no. 9, 2002, pages 1348-1356, XP008097346, ISSN: 0173-0835 (B1)

"Chapters 4, 5 and ass. exercises" In: Delcourt, M-O. et al: "Equilibres Chimiques en solution", De Boeck Univrsité (B2)

"DOTAREM 0.5 mmol/ml, solution for injection vials, Pre-Filled Syringes", , 21 October 2011 (2011-10-21), pages 1-4, XP003028305, Retrieved from the Internet: URL:http://www.health.gov.il/units/pharmac y/trufot/alonim/3768.pdf & Third party observations filed in parent case EP 2591807 (Feb 24, 2015, including analytical data of DOTAREM) & Presentation by the patentee (Feb 2005) made available in the internet in 2011 & Patentee's letter to healthcare professionals dated July 2008 & Decision to refuse the parent patent application EP 2 591 807 (jan. 24, 2017) (B2)

"Quality assurance of pharmaceuticals", WHO, 2007, pages iii/iv, 188, 193-194, (B2)

"chapter 6" In: Merbach and Toth: "The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging", 2001, Wiley (B2)

Anderson, N.: "Practical Process Research and Development, 1st Edition", 2000, Academic Press pages 223-247, (B2)

Data submitted by patentee on September 3, 2015 in the Examination proceedings of patent EP2799089 (B2)

Declaration under 37 CFR 1.132 submitted by the Patentee on March 30, 2018, in the examination proceedings of the corresponding American Patent application no. 15/140, 132: 'Implementation of the method of the invention on a laboratory scale' (B2)

Declaration under 37 CFR 1.132 submitted by the Patentee on March 30, 2018, in the examination proceedings of the corresponding American Patent application no. 15/140, 132: 'Implementation of the method of the invention on a pilot scale' (B2)

Dominique Meyer, Schaefer Michel, Bonnemain Bruno: "Gd-DOTA, A Potential MRI Contrast Agent Current Status of Physicochemical Knowledge", INVESTIGATIVE RADIOLOGY, Lippincott Williams & Wilkins, US, vol. 23, no. Suppl.1, 1 September 1988 (1988-09-01), pages S232-S235, XP055369149, US ISSN: 0020-9996, DOI: 10.1097/00004424-198809000-00050 (B2)

Dotarem 0.5 mmol/ml solution for injection in pre-filled syringes from AFSSAPS (B2)

Dotarem 0.5 mmol/ml solution from AFSSAPS (B2)

FR-A1- 2 596 992 (B2)

H. Gries: "Extracellular MRI contrast agents based on Gadolinium", Topics in Current Chemistry Topics in Current Chemistry, XP055308512, DOI: 10.1007/3-540-45733-X_1 [retrieved on 2016-10-07] (B2)

HAGAN ET AL: Anal Chem, vol. 60, 1988, pages 514-516, (B2)

MOI et al: Cancer Research (Supp), vol. 50, 1990, pages 789s-793s, (B2)

Mullin, J.W.: "Crystallization", 2001, Butterworth-Heinemann 4th ed pages 289-314, (B2)

Myerson, A.: "Handbook of Industrial Crystallization", 2002, Elsevier Inc pages 67-100, 249-266, (B2)

N/a: "Guidance for Industry PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance", Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) Office of Regulatory Affairs (ORA) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) Office of Regulatory Affairs (ORA), pages 1-16, XP055369155, Retrieved from the Internet: URL:https://www.fda.gov/downloads/drugs/gu idances/ucm070305.pdf [retrieved on 2017-05-03] (B2)

US-A- 4 639 365 (B2)

US-A- 5 049 667 (B2)

US-A- 5 362 475 (B2)

US-A- 5 650 133 (B2)

WO-A2-91/10645 (B2)

WO-A2-93/20852 (B2)

Weinemann H-J Et Al.: "Gadolinium Chelates: Chemistry, Safety, and Behavior" In: "Encyclopedia of Magnetic Resonance", 1 January 2007 (2007-01-01), XP055369153, pages 1-8, DOI: 10.1002/9780470034590.emrstm0183, (B2)

EP-A1- 0 481 526 (B1)